logo

Nabriva Therapeutics (NBRV)



Trade NBRV now with
  Date
  Headline
7/25/2018 4:05:10 PM Nabriva Therapeutics Announces Proposed Public Offering Of Ordinary Shares
7/24/2018 4:03:36 PM Nabriva Therapeutics Acquires Of Zavante Therapeutics
5/21/2018 7:36:52 AM Nabriva Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Clinical Trial Of Oral Lefamulin
5/16/2018 11:47:52 AM Wedbush Is Raising Nabriva Therapeutics (NBRV) FY18 Rev. Estimate To 16.3 M From 5.0 M
5/16/2018 11:47:38 AM Wedbush Is Lowering Nabriva Therapeutics (NBRV) Q4 18 Rev. Estimate To 1.0 M From 1.4 M
5/16/2018 11:47:25 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q3 18 Rev. Estimate To 6.7 M From 1.1 M
5/16/2018 11:47:11 AM Wedbush Is Lowering Nabriva Therapeutics (NBRV) Q2 18 Rev. Estimate To 1.0 M From 1.4 M
5/16/2018 11:46:46 AM Wedbush Is Raising Nabriva Therapeutics (NBRV) FY18 Estimate To -1.55 From -2.85
5/16/2018 11:46:25 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q4 18 Estimate To -0.41 From -0.61
5/16/2018 11:46:11 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q3 18 Estimate To -0.32 From -0.75
5/16/2018 11:45:55 AM Wedbush Is Increasing Nabriva Therapeutics (NBRV) Q2 18 Estimate To -0.46 From -0.74
5/8/2018 7:16:41 AM Nabriva Therapeutics Q1 Net Loss $13.3 Mln Or $0.36/Shr Vs Loss Of $15.2 Mln Or $0.56/Shr Last Year
3/27/2018 7:04:06 AM Nabriva Therapeutics, Roivant Sciences Enter Into License Agreement To Commercialize Lefamulin In Greater China
3/19/2018 2:02:41 PM Wedbush Is Lowering Nabriva Therapeutics (NBRV) 2018 Estimate To -2.85 From -1.85
3/19/2018 2:02:24 PM Wedbush Is Cutting Nabriva Therapeutics (NBRV) 4Q18 Estimate To -0.61 From -0.41
3/19/2018 2:02:09 PM Wedbush Is Lowering Nabriva Therapeutics (NBRV) 3Q18 Estimate To -0.75 From -0.48
3/19/2018 2:01:49 PM Wedbush Is Cutting Nabriva Therapeutics (NBRV) 2Q18 Estimate To -0.74 From -0.48
3/19/2018 2:01:37 PM Wedbush Is Lowering Nabriva Therapeutics (NBRV) 1Q18 Estimate To -0.75 From -0.48
3/19/2018 2:00:19 PM RBC Capital Markets Is Lowering Nabriva Therapeutics (NBRV) 2018 Rev. Estimate To 5.0 M From 5.9 M